1
|
Geng P, Zhao J, Li Q, Wang X, Qin W, Wang T, Shi X, Liu X, Chen J, Qiu H, Xu G. Z-Ligustilide Combined with Cisplatin Reduces PLPP1-Mediated Phospholipid Synthesis to Impair Cisplatin Resistance in Lung Cancer. Int J Mol Sci 2023; 24:17046. [PMID: 38069368 PMCID: PMC10706864 DOI: 10.3390/ijms242317046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2023] [Revised: 11/17/2023] [Accepted: 11/29/2023] [Indexed: 12/18/2023] Open
Abstract
Lung cancer is a malignant tumor with one of the highest morbidity and mortality rates in the world. Approximately 80-85% of lung cancer is diagnosed as non-small lung cancer (NSCLC), and its 5-year survival rate is only 21%. Cisplatin is a commonly used chemotherapy drug for the treatment of NSCLC. Its efficacy is often limited by the development of drug resistance after long-term treatment. Therefore, determining how to overcome cisplatin resistance, enhancing the sensitivity of cancer cells to cisplatin, and developing new therapeutic strategies are urgent clinical problems. Z-ligustilide is the main active ingredient of the Chinese medicine Angelica sinensis, and has anti-tumor activity. In the present study, we investigated the effect of the combination of Z-ligustilide and cisplatin (Z-ligustilide+cisplatin) on the resistance of cisplatin-resistant lung cancer cells and its mechanism of action. We found that Z-ligustilide+cisplatin decreased the cell viability, induced cell cycle arrest, and promoted the cell apoptosis of cisplatin-resistant lung cancer cells. Metabolomics combined with transcriptomics revealed that Z-ligustilide+cisplatin inhibited phospholipid synthesis by upregulating the expression of phospholipid phosphatase 1 (PLPP1). A further study showed that PLPP1 expression was positively correlated with good prognosis, whereas the knockdown of PLPP1 abolished the effects of Z-ligustilide+cisplatin on cell cycle and apoptosis. Specifically, Z-ligustilide+cisplatin inhibited the activation of protein kinase B (AKT) by reducing the levels of phosphatidylinositol 3,4,5-trisphosphate (PIP3). Z-ligustilide+cisplatin induced cell cycle arrest and promoted the cell apoptosis of cisplatin-resistant lung cancer cells by inhibiting PLPP1-mediated phospholipid synthesis. Our findings demonstrate that the combination of Z-Ligustilide and cisplatin is a promising approach to the chemotherapy of malignant tumors that are resistant to cisplatin.
Collapse
Affiliation(s)
- Pengyu Geng
- CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China; (P.G.); (J.Z.); (Q.L.); (X.W.); (W.Q.); (T.W.); (X.S.); (X.L.)
- Liaoning Province Key Laboratory of Metabolomics, Dalian 116023, China
| | - Jinhui Zhao
- CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China; (P.G.); (J.Z.); (Q.L.); (X.W.); (W.Q.); (T.W.); (X.S.); (X.L.)
- Liaoning Province Key Laboratory of Metabolomics, Dalian 116023, China
| | - Qi Li
- CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China; (P.G.); (J.Z.); (Q.L.); (X.W.); (W.Q.); (T.W.); (X.S.); (X.L.)
- Liaoning Province Key Laboratory of Metabolomics, Dalian 116023, China
| | - Xiaolin Wang
- CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China; (P.G.); (J.Z.); (Q.L.); (X.W.); (W.Q.); (T.W.); (X.S.); (X.L.)
- Liaoning Province Key Laboratory of Metabolomics, Dalian 116023, China
| | - Wangshu Qin
- CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China; (P.G.); (J.Z.); (Q.L.); (X.W.); (W.Q.); (T.W.); (X.S.); (X.L.)
- Liaoning Province Key Laboratory of Metabolomics, Dalian 116023, China
| | - Ting Wang
- CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China; (P.G.); (J.Z.); (Q.L.); (X.W.); (W.Q.); (T.W.); (X.S.); (X.L.)
- Liaoning Province Key Laboratory of Metabolomics, Dalian 116023, China
| | - Xianzhe Shi
- CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China; (P.G.); (J.Z.); (Q.L.); (X.W.); (W.Q.); (T.W.); (X.S.); (X.L.)
- Liaoning Province Key Laboratory of Metabolomics, Dalian 116023, China
| | - Xinyu Liu
- CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China; (P.G.); (J.Z.); (Q.L.); (X.W.); (W.Q.); (T.W.); (X.S.); (X.L.)
- Liaoning Province Key Laboratory of Metabolomics, Dalian 116023, China
| | - Jia Chen
- CAS Key Laboratory of Chemistry of Northwestern Plant Resources, Key Laboratory for Natural Medicine of Gansu Province, Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences, Lanzhou 730000, China; (J.C.); (H.Q.)
| | - Hongdeng Qiu
- CAS Key Laboratory of Chemistry of Northwestern Plant Resources, Key Laboratory for Natural Medicine of Gansu Province, Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences, Lanzhou 730000, China; (J.C.); (H.Q.)
| | - Guowang Xu
- CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China; (P.G.); (J.Z.); (Q.L.); (X.W.); (W.Q.); (T.W.); (X.S.); (X.L.)
- Liaoning Province Key Laboratory of Metabolomics, Dalian 116023, China
| |
Collapse
|
2
|
Park SJ, Joo SH, Lee N, Jang WJ, Seo JH, Jeong CH. ACY-241, an HDAC6 inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by inducing autophagy. Arch Pharm Res 2021; 44:1062-1075. [PMID: 34761352 DOI: 10.1007/s12272-021-01359-x] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2021] [Accepted: 11/01/2021] [Indexed: 10/19/2022]
Abstract
Histone deacetylase 6 (HDAC6) is a promising target for cancer treatment because it regulates cell mobility, protein trafficking, cell growth, apoptosis, and metastasis. However, the mechanism of HDAC6-induced anticancer drug resistance is unclear. In this study, we evaluated the anticancer effect of ACY-241, an HDAC6-selective inhibitor, on erlotinib-resistant pancreatic cancer cells that overexpress HDAC6. Our data revealed that ACY-241 hyperacetylated the HDAC6 substrate, α-tubulin, leading to a significant reduction in cell viability of erlotinib-resistant pancreatic cells, BxPC3-ER and HPAC-ER. Notably, a synergistic anticancer effect was observed in cells that received combined treatment with ACY-241 and erlotinib. Combined treatment effectively induced autophagy and inhibited autophagy through siLC3B, and siATG5 alleviated ACY-241-mediated cell death, as reflected by the recovery of PARP cleavage and apoptosis rates. In addition, combined ACY-241 and erlotinib treatment induced autophagy and subsequently, cell death by reducing AKT-mTOR activity and increasing phospho-AMPK signaling. Therefore, HDAC6 may be involved in the suppression of autophagy and acquisition of resistance to erlotinib in ER pancreatic cancer cells. ACY-241 to overcome erlotinib resistance could be an effective therapeutic strategy against pancreatic cancer.
Collapse
Affiliation(s)
- Seong-Jun Park
- College of Pharmacy, Keimyung University, 1095 Dalgubeil-daero, Daegu, 42601, South Korea
| | - Sang Hoon Joo
- Department of Pharmacy, Daegu Catholic University, Gyeongsan, 38430, South Korea
| | - Naeun Lee
- College of Pharmacy, Keimyung University, 1095 Dalgubeil-daero, Daegu, 42601, South Korea
| | - Won-Jun Jang
- College of Pharmacy, Keimyung University, 1095 Dalgubeil-daero, Daegu, 42601, South Korea
| | - Ji Hae Seo
- Department of Biochemistry, Keimyung University School of Medicine, 1095 Dalgubeil-daero, Daegu, 42601, South Korea.
| | - Chul-Ho Jeong
- College of Pharmacy, Keimyung University, 1095 Dalgubeil-daero, Daegu, 42601, South Korea.
| |
Collapse
|
3
|
Herrmann HA, Rusz M, Baier D, Jakupec MA, Keppler BK, Berger W, Koellensperger G, Zanghellini J. Thermodynamic Genome-Scale Metabolic Modeling of Metallodrug Resistance in Colorectal Cancer. Cancers (Basel) 2021; 13:cancers13164130. [PMID: 34439283 PMCID: PMC8391396 DOI: 10.3390/cancers13164130] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2021] [Revised: 07/23/2021] [Accepted: 08/03/2021] [Indexed: 12/11/2022] Open
Abstract
Simple Summary Cancer, but also its treatment, can lead to a reprogramming of cellular metabolism. These changes are observable in metabolite abundances, which can be unbiasedly measured via mass spectrometry metabolomics. However, even when the metabolome changes strongly, a (mechanistic) interpretation is difficult as metabolite levels do not necessarily directly correspond to pathway activities. Here we measure the changes of the cellular metabolome in colorectal cancer cell lines sensitive and resistant to the ruthenium-based drug BOLD-100/KP1339 and the platinum-based drug oxaliplatin. We map these changes onto a cancer-specific genome-scale metabolic model, which allows us not only to compute intracellular flux distributions, but also to disentangle drug-specific effects from growth differences from differences in metabolic adaptations due to resistance. Specifically, we find that resistance to BOLD-100/KP1339 induces more extensive reprogramming than oxaliplatin, especially with respect to fatty acid and amino acid metabolism. Abstract Background: Mass spectrometry-based metabolomics approaches provide an immense opportunity to enhance our understanding of the mechanisms that underpin the cellular reprogramming of cancers. Accurate comparative metabolic profiling of heterogeneous conditions, however, is still a challenge. Methods: Measuring both intracellular and extracellular metabolite concentrations, we constrain four instances of a thermodynamic genome-scale metabolic model of the HCT116 colorectal carcinoma cell line to compare the metabolic flux profiles of cells that are either sensitive or resistant to ruthenium- or platinum-based treatments with BOLD-100/KP1339 and oxaliplatin, respectively. Results: Normalizing according to growth rate and normalizing resistant cells according to their respective sensitive controls, we are able to dissect metabolic responses specific to the drug and to the resistance states. We find the normalization steps to be crucial in the interpretation of the metabolomics data and show that the metabolic reprogramming in resistant cells is limited to a select number of pathways. Conclusions: Here, we elucidate the key importance of normalization steps in the interpretation of metabolomics data, allowing us to uncover drug-specific metabolic reprogramming during acquired metal-drug resistance.
Collapse
Affiliation(s)
- Helena A. Herrmann
- Department of Analytical Chemistry, University of Vienna, 1090 Vienna, Austria; (H.A.H.); (M.R.)
| | - Mate Rusz
- Department of Analytical Chemistry, University of Vienna, 1090 Vienna, Austria; (H.A.H.); (M.R.)
- Institute of Inorganic Chemistry, University of Vienna, 1090 Vienna, Austria; (D.B.); (M.A.J.); (B.K.K.)
| | - Dina Baier
- Institute of Inorganic Chemistry, University of Vienna, 1090 Vienna, Austria; (D.B.); (M.A.J.); (B.K.K.)
| | - Michael A. Jakupec
- Institute of Inorganic Chemistry, University of Vienna, 1090 Vienna, Austria; (D.B.); (M.A.J.); (B.K.K.)
- Research Cluster Translational Cancer Therapy Research, University of Vienna and Medical University of Vienna, 1090 Vienna, Austria;
| | - Bernhard K. Keppler
- Institute of Inorganic Chemistry, University of Vienna, 1090 Vienna, Austria; (D.B.); (M.A.J.); (B.K.K.)
- Research Cluster Translational Cancer Therapy Research, University of Vienna and Medical University of Vienna, 1090 Vienna, Austria;
| | - Walter Berger
- Research Cluster Translational Cancer Therapy Research, University of Vienna and Medical University of Vienna, 1090 Vienna, Austria;
- Institute of Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria
| | - Gunda Koellensperger
- Department of Analytical Chemistry, University of Vienna, 1090 Vienna, Austria; (H.A.H.); (M.R.)
- Vienna Metabolomics Center (VIME), University of Vienna, 1090 Vienna, Austria
- Research Network Chemistry Meets Microbiology, University of Vienna, 1090 Vienna, Austria
- Correspondence: (G.K.); (J.Z.)
| | - Jürgen Zanghellini
- Department of Analytical Chemistry, University of Vienna, 1090 Vienna, Austria; (H.A.H.); (M.R.)
- Correspondence: (G.K.); (J.Z.)
| |
Collapse
|
4
|
Metabolic Reprogramming of Chemoresistant Cancer Cells and the Potential Significance of Metabolic Regulation in the Reversal of Cancer Chemoresistance. Metabolites 2020; 10:metabo10070289. [PMID: 32708822 PMCID: PMC7408410 DOI: 10.3390/metabo10070289] [Citation(s) in RCA: 63] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2020] [Revised: 06/15/2020] [Accepted: 07/04/2020] [Indexed: 02/07/2023] Open
Abstract
Metabolic reprogramming is one of the hallmarks of tumors. Alterations of cellular metabolism not only contribute to tumor development, but also mediate the resistance of tumor cells to antitumor drugs. The metabolic response of tumor cells to various chemotherapy drugs can be analyzed by metabolomics. Although cancer cells have experienced metabolic reprogramming, the metabolism of drug resistant cancer cells has been further modified. Metabolic adaptations of drug resistant cells to chemotherapeutics involve redox, lipid metabolism, bioenergetics, glycolysis, polyamine synthesis and so on. The proposed metabolic mechanisms of drug resistance include the increase of glucose and glutamine demand, active pathways of glutaminolysis and glycolysis, promotion of NADPH from the pentose phosphate pathway, adaptive mitochondrial reprogramming, activation of fatty acid oxidation, and up-regulation of ornithine decarboxylase for polyamine production. Several genes are associated with metabolic reprogramming and drug resistance. Intervening regulatory points described above or targeting key genes in several important metabolic pathways may restore cell sensitivity to chemotherapy. This paper reviews the metabolic changes of tumor cells during the development of chemoresistance and discusses the potential of reversing chemoresistance by metabolic regulation.
Collapse
|
5
|
Dewan N, Shukla V, Rehni AK, Koronowski KB, Klingbeil KD, Stradecki‐Cohan H, Garrett TJ, Rundek T, Perez‐Pinzon MA, Dave KR. Exposure to recurrent hypoglycemia alters hippocampal metabolism in treated streptozotocin-induced diabetic rats. CNS Neurosci Ther 2020; 26:126-135. [PMID: 31282100 PMCID: PMC6930817 DOI: 10.1111/cns.13186] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2019] [Revised: 05/31/2019] [Accepted: 06/04/2019] [Indexed: 12/13/2022] Open
Abstract
AIMS Exposure to recurrent hypoglycemia (RH) is common in diabetic patients receiving glucose-lowering therapies and is implicated in causing cognitive impairments. Despite the significant effect of RH on hippocampal function, the underlying mechanisms are currently unknown. Our goal was to determine the effect of RH exposure on hippocampal metabolism in treated streptozotocin-diabetic rats. METHODS Hyperglycemia was corrected by insulin pellet implantation. Insulin-treated diabetic (ITD) rats were exposed to mild/moderate RH once a day for 5 consecutive days. RESULTS The effect of RH on hippocampal metabolism revealed 65 significantly altered metabolites in the RH group compared with controls. Several significant differences in metabolite levels belonging to major pathways (eg, Krebs cycle, gluconeogenesis, and amino acid metabolism) were discovered in RH-exposed ITD rats when compared to a control group. Key glycolytic enzymes including hexokinase, phosphofructokinase, and pyruvate kinase were affected by RH exposure. CONCLUSION Our results demonstrate that the exposure to RH leads to metabolomics alterations in the hippocampus of insulin-treated streptozotocin-diabetic rats. Understanding how RH affects hippocampal metabolism may help attenuate the adverse effects of RH on hippocampal functions.
Collapse
Affiliation(s)
- Neelesh Dewan
- Peritz Scheinberg Cerebral Vascular Disease Research LaboratoriesUniversity of Miami School of MedicineMiamiFloridaUSA
- Department of NeurologyUniversity of Miami School of MedicineMiamiFloridaUSA
| | - Vibha Shukla
- Peritz Scheinberg Cerebral Vascular Disease Research LaboratoriesUniversity of Miami School of MedicineMiamiFloridaUSA
- Department of NeurologyUniversity of Miami School of MedicineMiamiFloridaUSA
| | - Ashish K. Rehni
- Peritz Scheinberg Cerebral Vascular Disease Research LaboratoriesUniversity of Miami School of MedicineMiamiFloridaUSA
- Department of NeurologyUniversity of Miami School of MedicineMiamiFloridaUSA
| | - Kevin B. Koronowski
- Peritz Scheinberg Cerebral Vascular Disease Research LaboratoriesUniversity of Miami School of MedicineMiamiFloridaUSA
- Department of NeurologyUniversity of Miami School of MedicineMiamiFloridaUSA
- Neuroscience ProgramUniversity of Miami School of MedicineMiamiFloridaUSA
| | - Kyle D. Klingbeil
- Peritz Scheinberg Cerebral Vascular Disease Research LaboratoriesUniversity of Miami School of MedicineMiamiFloridaUSA
- Department of NeurologyUniversity of Miami School of MedicineMiamiFloridaUSA
| | - Holly Stradecki‐Cohan
- Peritz Scheinberg Cerebral Vascular Disease Research LaboratoriesUniversity of Miami School of MedicineMiamiFloridaUSA
- Department of NeurologyUniversity of Miami School of MedicineMiamiFloridaUSA
- Neuroscience ProgramUniversity of Miami School of MedicineMiamiFloridaUSA
| | - Timothy J. Garrett
- Southeast Center for Integrated Metabolomics, Clinical and Translational Science InstituteUniversity of FloridaGainesvilleFloridaUSA
| | - Tatjana Rundek
- Department of NeurologyUniversity of Miami School of MedicineMiamiFloridaUSA
- Evelyn F. McKnight Brain InstituteUniversity of Miami School of MedicineMiamiFloridaUSA
| | - Miguel A. Perez‐Pinzon
- Peritz Scheinberg Cerebral Vascular Disease Research LaboratoriesUniversity of Miami School of MedicineMiamiFloridaUSA
- Department of NeurologyUniversity of Miami School of MedicineMiamiFloridaUSA
- Neuroscience ProgramUniversity of Miami School of MedicineMiamiFloridaUSA
- Evelyn F. McKnight Brain InstituteUniversity of Miami School of MedicineMiamiFloridaUSA
| | - Kunjan R. Dave
- Peritz Scheinberg Cerebral Vascular Disease Research LaboratoriesUniversity of Miami School of MedicineMiamiFloridaUSA
- Department of NeurologyUniversity of Miami School of MedicineMiamiFloridaUSA
- Neuroscience ProgramUniversity of Miami School of MedicineMiamiFloridaUSA
- Evelyn F. McKnight Brain InstituteUniversity of Miami School of MedicineMiamiFloridaUSA
| |
Collapse
|
6
|
Xu M, Shen C, Zheng H, Xu Y, Xue C, Zhu B, Hu J. Metabolomic analysis of acerola cherry (Malpighia emarginata) fruit during ripening development via UPLC-Q-TOF and contribution to the antioxidant activity. Food Res Int 2019; 130:108915. [PMID: 32156365 DOI: 10.1016/j.foodres.2019.108915] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2019] [Revised: 12/07/2019] [Accepted: 12/15/2019] [Indexed: 01/12/2023]
Abstract
Acerola cherry (Malpighia emarginata D.C.) is a tropical fruit of great economic and nutritional value due to its high content of vitamin C. However, there is little information available about which ripening stage of Acerola cherry can provide the best nutrients. In the current study, the chemical variation at two developmental stages (immature and mature) were investigated by metabolic profiling, and the biological properties of Acerola cherry and its antioxidant assays at four developmental stages were measured, respectively. Through comprehensive metabolites analysis via ultra-high-performance liquid chromatography coupled with quadrupole-time-of-flight mass spectrometry system (UPLC-QTOF), 1896 annotated metabolite features were obtained, and 133 metabolites were finally identified according to the MS/MS fragments compared with these standards in in-house database. Statistically differences in the levels of amino acids, flavonoids, lipids, terpenoids and ascorbic acids were found between mature and immature fruits. Interestingly, most of differential accumulated amino acids, flavonoids, lipids, and terpenoids predominantly accumulated in the mature fruits and ascorbic acid predominantly accumulated in the immature fruits. On the other hand, their antioxidant activities were compared. The alcoholic extract of immature acerola fruit possessed better scavenging ability of DPPH and ABTS than the mature one. The well correlations were found between the antioxidant potential with its content of ascorbic acid (r = 0.9803 and 0.9897, respectively). In conclusion, Acerola cherry showed very different metabolite profile and antioxidant activities during the fruit ripening development. The maturity of Acerola cherry has to be considered when it is being used for health food products.
Collapse
Affiliation(s)
- Mingfeng Xu
- School of Food Science and Technology, Dalian Polytechnic University, Dalian 116034, China; College of Life and Environmental Sciences, Hangzhou Normal University, Hangzhou 310036, China
| | - Chenjia Shen
- College of Life and Environmental Sciences, Hangzhou Normal University, Hangzhou 310036, China
| | - Han Zheng
- School of Food Science and Technology, Dalian Polytechnic University, Dalian 116034, China
| | - Yunsheng Xu
- School of Food Science and Engineering, Hainan Tropical Ocean University, Sanya 572022 China
| | - Changfeng Xue
- School of Food Science and Engineering, Hainan Tropical Ocean University, Sanya 572022 China
| | - Beiwei Zhu
- School of Food Science and Technology, Dalian Polytechnic University, Dalian 116034, China
| | - Jiangning Hu
- School of Food Science and Technology, Dalian Polytechnic University, Dalian 116034, China.
| |
Collapse
|
7
|
Lee N, Jang WJ, Seo JH, Lee S, Jeong CH. 2-Deoxy-d-Glucose-Induced Metabolic Alteration in Human Oral Squamous SCC15 Cells: Involvement of N-Glycosylation of Axl and Met. Metabolites 2019; 9:metabo9090188. [PMID: 31533338 PMCID: PMC6780519 DOI: 10.3390/metabo9090188] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2019] [Revised: 09/07/2019] [Accepted: 09/12/2019] [Indexed: 12/20/2022] Open
Abstract
One of the most prominent hallmarks of cancer cells is their dependency on the glycolytic pathway for energy production. As a potent inhibitor of glycolysis, 2-deoxy-d-glucose (2DG) has been proposed for cancer treatment and extensively investigated in clinical studies. Moreover, 2DG has been reported to interfere with other biological processes including glycosylation. To further understand the overall effect of and metabolic alteration by 2DG, we performed biochemical and metabolomics analyses on oral squamous cell carcinoma cell lines. In this study, we found that 2DG more effectively reduced glucose consumption and lactate level in SCC15 cells than in SCC4 cells, which are less dependent on glycolysis. Coincidentally, 2DG impaired N-linked glycosylation of the key oncogenic receptors Axl and Met in SCC15 cells, thereby reducing the cell viability and colony formation ability. The impaired processes of glycolysis and N-linked glycosylation were restored by exogenous addition of pyruvate and mannose, respectively. Additionally, our targeted metabolomics analysis revealed significant alterations in the metabolites, including amino acids, biogenic amines, glycerophospholipids, and sphingolipids, caused by the impairment of glycolysis and N-linked glycosylation. These observations suggest that alterations of these metabolites may be responsible for the phenotypic and metabolic changes in SCC15 cells induced by 2DG. Moreover, our data suggest that N-linked glycosylation of Axl and Met may contribute to the maintenance of cancer properties in SCC15 cells. Further studies are needed to elucidate the roles of these altered metabolites to provide novel therapeutic targets for treating human oral cancer.
Collapse
Affiliation(s)
- Naeun Lee
- College of Pharmacy, Keimyung University, Daegu 42601, Korea.
| | - Won-Jun Jang
- College of Pharmacy, Keimyung University, Daegu 42601, Korea.
| | - Ji Hae Seo
- Department of Biochemistry, Keimyung University School of Medicine, Daegu 42601, Korea.
| | - Sooyeun Lee
- College of Pharmacy, Keimyung University, Daegu 42601, Korea.
| | - Chul-Ho Jeong
- College of Pharmacy, Keimyung University, Daegu 42601, Korea.
| |
Collapse
|
8
|
Hong W, Zhao Y, Cao L, Cao D, Zhao Z, Jin J. [Metabolomics Study on the Differences of Endogenous Small Molecule
between A549/DDP and A549 Cells Based on High Solution UPLC-TOF-MS]. ZHONGGUO FEI AI ZA ZHI = CHINESE JOURNAL OF LUNG CANCER 2018; 21:571-577. [PMID: 30172262 PMCID: PMC6105355 DOI: 10.3779/j.issn.1009-3419.2018.08.01] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
背景与目的 顺铂获得性耐药是非小细胞肺癌(non-small cell lung cancer, NSCLC)化疗中至关重要并且有待进一步解决的问题。近年来通过细胞培养获得肿瘤耐药细胞,并将其作为代谢组学研究对象,寻找差异代谢物,获得潜在生物标志物,可以有效地为临床研究和治疗提供参考。本研究旨在通过代谢组学分析获取与顺铂耐药性相关的代谢物信息。 方法 培养NSCLC细胞A549与其顺铂获得性耐药细胞A549/DDP后进行代谢物提取,通过超高效液相色谱-飞行时间质谱法对两种细胞的内源性小分子进行代谢组学分析,获取代谢差异物。 结果 通过数据分析处理,获得40种差异代谢物,主要涉及磷脂、脂肪酸、氨基酸和能量代谢相关代谢物。 结论 A549/DDP细胞的耐药性可能由于细胞膜结构的改变以及相关代谢途径的变化而导致。
Collapse
Affiliation(s)
- Weipeng Hong
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China
| | - Yonghua Zhao
- Clinical Lab, People's Hospital of Nanzhang County, Nanzhang 441500, China
| | - Lin Cao
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China
| | - Di Cao
- School of Chinese Materia Medica, Guangzhou University of Chinese Medicine, Guangzhou 510006, China
| | - Zhongxiang Zhao
- School of Chinese Materia Medica, Guangzhou University of Chinese Medicine, Guangzhou 510006, China
| | - Jing Jin
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China
| |
Collapse
|
9
|
Jang WJ, Choi B, Song SH, Lee N, Kim DJ, Lee S, Jeong CH. Multi-omics analysis reveals that ornithine decarboxylase contributes to erlotinib resistance in pancreatic cancer cells. Oncotarget 2017; 8:92727-92742. [PMID: 29190951 PMCID: PMC5696217 DOI: 10.18632/oncotarget.21572] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2017] [Accepted: 09/04/2017] [Indexed: 12/30/2022] Open
Abstract
Molecular and metabolic alterations in cancer cells are one of the leading causes of acquired resistance to chemotherapeutics. In this study, we explored an experimental strategy to identify which of these alterations can induce erlotinib resistance in human pancreatic cancer. Using genetically matched erlotinib-sensitive (BxPC-3) and erlotinib-resistant (BxPC-3ER) pancreatic cancer cells, we conducted a multi-omics analysis of metabolomes and transcriptomes in these cells. Untargeted and targeted metabolomic analyses revealed significant changes in metabolic pathways involved in the regulation of polyamines, amino acids, and fatty acids. Further transcriptomic analysis identified that ornithine decarboxylase (ODC) and its major metabolite, putrescine, contribute to the acquisition of erlotinib resistance in BxPC-3ER cells. Notably, either pharmacological or genetic blockage of ODC was able to restore erlotinib sensitivity, and this could be rescued by treatment with exogenous putrescine in erlotinib-resistant BxPC-3ER cells. Moreover, using a panel of cancer cells we demonstrated that ODC expression levels in cancer cells are inversely correlated with sensitivity to chemotherapeutics. Taken together, our findings will begin to uncover mechanisms of acquired drug resistance and ultimately help to identify potential therapeutic markers in cancer.
Collapse
Affiliation(s)
- Won-Jun Jang
- College of Pharmacy, Keimyung University, Daegu 42601, Republic of Korea
| | - Boyeon Choi
- College of Pharmacy, Keimyung University, Daegu 42601, Republic of Korea
| | - Sang-Hoon Song
- College of Pharmacy, Keimyung University, Daegu 42601, Republic of Korea
| | - Naeun Lee
- College of Pharmacy, Keimyung University, Daegu 42601, Republic of Korea
| | - Dong-Joon Kim
- China-US (Henan) Hormel Cancer Institute, Zhengzhou 450008, China
| | - Sooyeun Lee
- College of Pharmacy, Keimyung University, Daegu 42601, Republic of Korea
| | - Chul-Ho Jeong
- College of Pharmacy, Keimyung University, Daegu 42601, Republic of Korea
| |
Collapse
|